Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis

Shariat, Shahrokh F.; Ashfaq, Raheela; Sagalowsky, Arthur I.; Lotan, Yair

doi:10.1016/j.humpath.2006.05.017

Cited by 85 publications

(82 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with muscleinvasive disease treated with radical cystectomy, p27 was the second most powerful cell cycle regulator after p53 for prediction of bladder cancer recurrence and survival. 27,28 Apoptosis (programmed cell death) results from a cascade of intrinsic and extrinsic signals and depends on the balance between pro-and anti-apoptotic proteins. 34 Caspase-3 is a pro-apoptotic enzyme that has been associated with higher pathologic grade, stage and presence of lymph node metastasis in radical cystectomy specimens.…”

Section: Biomarkers Of Prognosis and Therapeutic Efficacymentioning

confidence: 99%

“…Biomarkers that enhance the predictive ability of standard clinicopathologic information and optimize prognostication are being discovered. [19][20][21][22][23][24][25][26][27][28][29][30] In addition, advanced technologies offer a systematic approach for identifying active targets for drug discovery and tailored therapeutics in bladder cancer. The method described here defines a "personalized selection" approach to advanced bladder cancer within this increasingly tailored diagnostic and therapeutic framework, since optimizing management of a patient's This review explores recent advances laying the groundwork toward making "personalized selection" a reality for patients with muscle invasive and metastatic bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Ehdaie

Smith

Theodorescu

2013

CUAJ

View full text Add to dashboard Cite

The past decade has provided an improved understanding of the molecular mechanism of bladder cancer by defining distinct pathways in tumorigenesis and progression. Advances in technologies, such as high-throughput transcript profiling, microarrays and proteomics, offer a systematic approach to identifying targets for bladder cancer diagnostics and drug discovery. This review presents a select outline of the advances in the development of biomarkers and targets for patient prognosis and therapy selection. This paper describes a representative cohort of recent studies that have the potential to significantly impact the management of muscle invasive and metastatic urothelial carcinoma of the bladder. Space constraints do not permit this review to be comprehensive and we apologize to the authors whose work we do not cite.

show abstract

Section: Biomarkers Of Prognosis and Therapeutic Efficacymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Ehdaie

Smith

Theodorescu

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Staining and scoring protocols for cyclin E1, p53, p21, pRB, and p27 were performed as described elsewhere. 20,24,27,30 Multiple positive and negative control sections were included in each run.…”

Section: Immunohistochemistry and Scoringmentioning

confidence: 99%

“…[15][16][17][18][19][20][21][22][23][24][25][26][27] Several studies have shown that accumulation of altered expression of several of these immunohistochemical markers adds important prognostic information in patients treated with radical cystectomy. [15][16][17][18][19][20][21][22][23][24][25][26][27][28] A clinical trial is under way testing whether alterations of p53 nuclear expression can be used prospectively to identify high-risk patients and whether there is a benefit to administering adjuvant methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (M-VAC) chemotherapy in p53-altered patients. 25,26,29 In the present study we hypothesized that the expression of a panel of established cell cycle regulators (ie, p53, pRB, p21, p27, and cyclin E1) could help identify patients with pTa-3 N0M0 UCB who are at increased risk for disease progression and therefore would be candidates for systemic adjuvant chemotherapy.…”

mentioning

confidence: 99%

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

Shariat

Karakiewicz

Ashfaq

et al. 2007

Cancer

Self Cite

183

132

View full text Add to dashboard Cite

BACKGROUND.Tested was whether the assessment of 5 established bladder cancer biomarkers (p53, pRB, p21, p27, and cyclin E1) could improve the ability to predict disease recurrence and cancer‐specific survival after radical cystectomy in patients with pTa‐3N0M0 urothelial carcinoma of the bladder (UCB).METHODS.The study comprised 191 patients with pTa‐3N0M0 UCB treated with radical cystectomy and bilateral lymphadenectomy (median follow‐up, 3.1 years). Biomarker expression was assayed on serial tissue microarray slides using quantitative immunohistochemistry using advanced cell imaging and color detection software. Predictive accuracy was quantified using the concordance index and 200‐bootstrap resamples were used to reduce overfit bias. Bootstrap‐adjusted predictive accuracy estimates were compared using the Mantel‐Haenszel test.RESULTS.UCB recurred in 36 (18.8%) patients and 30 (15.7%) died of bladder cancer; 157 (82.2%) patients had altered expression of at least 1 biomarker. In univariate analyses the number of altered biomarkers had the highest predictive accuracy for both disease recurrence (76.8%, P < .001) and cancer‐specific mortality (78.3%, P < .001). Addition of the number of altered biomarkers increased the predictive accuracy of nomograms based on the TNM staging system for disease recurrence and cancer‐specific mortality by 10.9% (83.4% vs 72.5%, P < .001) and 8.6% (86.9% vs 78.3, P < .001), respectively.CONCLUSIONS.Assessment of the number of altered biomarkers in the cystectomy specimen improves the prediction of bladder cancer recurrence and survival in patients with pTa‐3N0M0 disease. Prospective evaluation of alteration in these biomarkers can help identify patients who would benefit from adjuvant treatment after radical cystectomy. Cancer 2008. © 2007 American Cancer Society.

show abstract

“…Immunohistochemical staining was also performed using antibodies against Ki-67, cyclin E1, cyclin D1, p53, p21, pRB, p27, bcl-2, caspase-3 and survivin on serial sections from the same paraffin-embedded tissue microarray blocks (28). Immunoglobulins from un-immunized rabbits and/or non-specific IgG1 monoclonal antibody were used as negative controls.…”

Section: Immunohistochemical Staining and Scoringmentioning

confidence: 99%

Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

et al. 2007

Self Cite

View full text Add to dashboard Cite

As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathological parameter, tumor's biological behavior or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or non-tumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63/74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104/202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33/50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including micro-luminal, basal-laminal, cytoplasmic or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence and bladder cancer-specific mortality (p=0.042, p=0.035, p=0.023 and p=0.022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27 and cyclin D1, thus excluding a functional link between these two groups of proteins. Our data demonstrate for the first time that persistent UP expression is ¶ Send correspondence to: Dr. Xue-Ru Wu, Department of Urology, New York University School of Medicine, 423 E23 Street, Room 18064S, Veterans Affairs Medical Center in Manhattan, New York, NY 10010. * These authors contributed equally to this work.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access

show abstract

Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis

Cited by 85 publications

References 25 publications

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

Contact Info

Product

Resources

About